Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02433808 · ClinicalTrials.gov registry record · Phase 4
Neostigmine Reversal And Neuromuscular Recovery
A Phase 4 study, sponsored by Endeavor Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT02433808 is a Phase 4 study that has completed, run by Endeavor Health. The registered enrollment target is 120 participants.
The verdict
NCT02433808, a Phase 4 study, has completed, sponsored by Endeavor Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
Patients undergoing surgery often receive paralytic agents (or neuromuscular blocking agents (NMBAs)) to facilitate the procedure. At the end of surgery, the effects NMBAs are reversed with a drug called neostigmine. The use of neostigmine significantly reduces the risk that a patient will be left with muscle weakness in the recovery room. Many anesthesiologists routinely use neostigmine because postoperative muscle weakness may lead to adverse events after surgery. Other anesthesiologists do not routinely administer neostigmine in the operating room because of concerns about potential side effects. Surprisingly, some investigators have reported that neostigmine-induced muscle weakness may occur if the drug is given when the effects of the NMBAs have completely worn off. In contrast, other investigators have not observed this side effect when neostigmine was given at the end of surgery. The aim of this study is to determine whether neostigmine use is associated with muscle weakness when it is given at the time of nearly complete recovery from NMBAs. Muscle strength will be measured using a sensitive monitor (TOF-Watch-SX) and through an examination of the patient for evidence of muscle weakness. Patients will also be evaluated how they recover from anesthesia and surgery.
Interventions
- DRUG Neostigmine Group
- OTHER No Neostigmine group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02433808
The ClinicalTrials.gov registry entry for NCT02433808 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Neostigmine Group is the first listed.
NCT02433808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02433808 about?
NCT02433808 is a clinical study titled "Neostigmine Reversal And Neuromuscular Recovery". Patients undergoing surgery often receive paralytic agents (or neuromuscular blocking agents (NMBAs)) to facilitate the procedure. At the end of surgery, the effects NMBAs are reversed with a drug called neostigmine. The use of neostigmine significantly reduces the risk that a patient will be left w...
What is the current status of trial NCT02433808?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2015-04. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02433808?
The interventions under investigation include: Neostigmine Group (DRUG), No Neostigmine group (OTHER).
Who is sponsoring clinical trial NCT02433808?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.